A New Frontier in Dengue Treatment: A Monoclonal Antibody Trial Shows Promise
Table of Contents
- 1. A New Frontier in Dengue Treatment: A Monoclonal Antibody Trial Shows Promise
- 2. What are the potential key outcomes of the Phase 2 clinical trial?
- 3. A New Frontier in Dengue Treatment: An Interview with Dr. Sarah Chen
- 4. Interview with Dr. sarah Chen, Lead Investigator, AV-1 Dengue Trial
- 5. Archyde News: Dr. Chen, thank you for speaking with us.Can you tell us about the significance of this trial for patients suffering from dengue fever?
- 6. Archyde News: What makes AV-1 a unique and promising candidate for dengue treatment?
- 7. Archyde News: How does this trial work, and what are the key objectives?
- 8. Archyde News: What are your hopes for the future of AV-1 if this trial is successful?
- 9. Archyde News: What implications could this breakthrough have for global health?
- 10. Archyde News: This is truly exciting news. Dr. Chen, thank you for your time and for your dedication to this vital research.
Dengue fever, a mosquito-borne illness affecting hundreds of millions worldwide, poses a meaningful public health threat. The disease, characterized by severe headaches, body aches, nausea, fever, and a distinctive rash, can progress to life-threatening complications in one in twenty cases. Currently, there is no FDA-approved treatment for dengue, leaving healthcare providers with limited options for critically ill patients.
“When caring for a patient who is critically ill with dengue, healthcare providers have few options other than providing supportive care. We must find safe and effective therapeutics to provide much-needed relief to people suffering from dengue,” explains Dr. Jeanne Marrazzo, Director of the National Institute of Allergy and Infectious Diseases (NIAID).
Hope is on the horizon with a new phase 2 clinical trial, supported by the National Institutes of Health (NIH), that is investigating the potential of AV-1, an experimental human monoclonal antibody developed by AbViro. This investigational therapeutic is designed to mitigate the symptoms of dengue virus infection when administered both before and after exposure.
The Phase 2 trial will enroll 84 healthy adult volunteers across two sites: the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore and the University of Vermont vaccine Testing Center in Burlington. Participants will be randomly assigned to receive either AV-1 one day before or four days after being challenged with a weakened strain of the dengue virus. The study will assess the safety and efficacy of three different dosage levels of AV-1 (100 mg, 300 mg, and 900 mg) administered intravenously.Prior research, including a Phase 1 trial also supported by the NIAID, has already demonstrated the safety of AV-1 in humans, paving the way for this larger trial. Previous studies using the attenuated dengue virus challenge have shown that most volunteers develop a rash and some experiance mild symptoms, such as joint and muscle pain or headache. However, no volunteers have developed dengue fever or severe dengue.
This new trial holds significant promise for finding a much-needed treatment for dengue.If accomplished, further clinical evaluations will be pursued to determine the full potential of AV-1 in combating this serious global health concern. For more detailed details about the study,you can visit ClinicalTrials.gov and search for the identifier NCT06799741.
What are the potential key outcomes of the Phase 2 clinical trial?
A New Frontier in Dengue Treatment: An Interview with Dr. Sarah Chen
Dengue fever, a mosquito-borne illness affecting hundreds of millions worldwide, poses a important public health threat. Currently, there is no FDA-approved treatment for dengue, leaving healthcare providers with limited options for critically ill patients. Though, a new phase 2 clinical trial is investigating the potential of AV-1, an experimental monoclonal antibody, too offer much-needed relief.
Interview with Dr. sarah Chen, Lead Investigator, AV-1 Dengue Trial
Dr. Sarah Chen is the lead investigator for the Phase 2 clinical trial evaluating the safety and efficacy of AV-1, a novel monoclonal antibody, in the treatment of dengue fever. We spoke with dr. Chen to learn more about this promising new therapy.
Archyde News: Dr. Chen, thank you for speaking with us.Can you tell us about the significance of this trial for patients suffering from dengue fever?
Dr. Chen: Your welcome. Dengue fever is a serious disease that can cause debilitating symptoms and, in severe cases, even death. Currently, there are no FDA-approved antiviral treatments for dengue. This trial represents a crucial step forward in our quest to develop a safe and effective therapeutic option for patients.
Archyde News: What makes AV-1 a unique and promising candidate for dengue treatment?
dr. Chen: AV-1 is a human monoclonal antibody specifically designed to target the dengue virus.Unlike existing treatment options,which primarily focus on symptom management,AV-1 aims to directly neutralize the virus,possibly preventing or lessening the severity of the disease.
Archyde News: How does this trial work, and what are the key objectives?
dr. Chen: The Phase 2 trial is a randomized, placebo-controlled study. We will be enlisting healthy adult volunteers who will be challenged with a weakened strain of the dengue virus. Participants will receive different dosages of AV-1 either one day before or four days after exposure to the virus. We will be carefully monitoring for safety and efficacy,assessing the impact of AV-1 on both the viral load and the development of associated symptoms.
Archyde News: What are your hopes for the future of AV-1 if this trial is successful?
Dr. Chen: Our hope is that AV-1 will become a valuable tool in the fight against dengue. If the trial demonstrates promising results, we will move forward with larger-scale trials to further evaluate its safety and effectiveness. Ultimately, we aim to make AV-1 available to patients worldwide, contributing to a significant reduction in the burden of this debilitating disease.
Archyde News: What implications could this breakthrough have for global health?
Dr. Chen: The potential impact is enormous. Dengue fever affects millions of people each year, primarily in tropical and subtropical regions.Having an effective treatment would be a major public health victory, saving lives and improving the well-being of countless individuals.
Archyde News: This is truly exciting news. Dr. Chen, thank you for your time and for your dedication to this vital research.
Dr. chen: You’re very welcome.
